Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | What to look forward to at ASH 2022 in the field of Waldenström’s macroglobulinemia

Steven Treon • 28 Oct 2022
ASH 2022 IWWM-11 2022
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia BTK inhibitors

In this video, Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, highlights what he is looking forward to at the 2022 ASH Annual Meeting, including updates on next-generation Bruton’s tyrosine kinase (BTK) inhibitors, and the importance of biomarkers in Waldenström’s macroglobulinemia (WM). This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Steven Treon

1:59
Updates in the response criteria for Waldenström’s macroglobulinemia
Steven Treon • 29 Sep 2023
2:23
Practical considerations when treating patients with WM: exciting agents & combinations
Steven Treon • 29 Sep 2023
1:54
Selecting the correct BTK inhibitor for patients with WM: lessons learned from the ASPEN trial
Steven Treon • 29 Sep 2023
1:47
Exciting updates in Waldenström’s macroglobulinemia: the value of BTK inhibitors
Steven Treon • 29 Sep 2023

Related Videos

2:04
Salvage treatment options following CAR-T failure in DLBCL
Jaromir Tomasik • 17 Apr 2024
1:55
Exploring first-line CAR-T therapy for the treatment of DLBCL
Wendy Osborne • 22 Apr 2024
3:29
CAR-T therapy as the SoC in 2L LBCL and barriers that remain
Wendy Osborne • 22 Apr 2024
2:32
Preventative therapeutic phlebotomies for patients with EPP
Rita Beier • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals